Pharmacologic treatment of male breast cancer

被引:17
作者
Hayes, Teresa G. [1 ]
机构
[1] Baylor Coll Med, Hematol Oncol Sect, Dept Vet Affairs Med Ctr, Houston, TX 77030 USA
关键词
aromatase; chemotherapy; hormonal therapy; male breast cancer; orchiectomy; tamoxifen; FIRST-LINE THERAPY; PROGNOSTIC-FACTORS; ADJUVANT CHEMOTHERAPY; AROMATASE INHIBITORS; HORMONAL-THERAPY; POSTMENOPAUSAL WOMEN; COMPLETE REMISSION; BRCA2; MUTATIONS; METASTATIC CARCINOMA; PREMENOPAUSAL WOMEN;
D O I
10.1517/14656560903200634
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Male breast cancer is an uncommon condition. It often occurs in settings in which there is an imbalance between androgens and oestrogens. Genetics plays an important role, as many cases are associated with mutations in BRCA2 or other genes. Male breast cancer occurs at an older age than female breast cancer and is frequently diagnosed at a later stage. Tumors are predominantly oestrogen and progesterone positive. Prognosis is approximately equivalent to that of breast cancer in females when matched for age, stage and hormonal receptors. The recommended treatment for male breast cancer is similar to that for breast cancer in postmenopausal females. However, the presence of androgens in males has a strong effect on the hormonal milieu and the ability of male patients to respond to hormonal agents. When pharmacologic treatment is required, tamoxifen is effective for first-line therapy. Other hormonal approaches such as orchiectomy, aromatase inhibitors and androgen ablation may be useful in later lines of therapy.
引用
收藏
页码:2499 / 2510
页数:12
相关论文
共 218 条
[1]
ABELE R, 1981, NEW ENGL J MED, V305, P1091
[2]
Fulvestrant in advanced male breast cancer [J].
Agrawal, Amit ;
Cheung, Kwok-Leung ;
Robertson, John F. R. .
BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (01) :123-123
[3]
TAMOXIFEN IN ADVANCED MALE BREAST-CANCER [J].
AISNER, J ;
ROSS, DD ;
WIERNIK, PH .
ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (04) :480-481
[4]
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients [J].
Alexandre, J ;
Bleuzen, P ;
Bonneterre, J ;
Sutherland, W ;
Misset, JL ;
Guastalla, JP ;
Viens, P ;
Faivre, S ;
Chahine, A ;
Spielman, M ;
Bensmaïne, A ;
Marty, M ;
Mahjoubi, M ;
Cvitkovic, E .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :562-573
[5]
ANDERSON WF, 2001, P AN M AM SOC CLIN, V20, pA1691
[6]
ANDERSON WF, 2008 ASCO BREAST CAN
[7]
Male breast cancer -: A reappraisal of clinical and biologic indicators of prognosis [J].
André, S ;
Fonseca, I ;
Pinto, AE ;
Cardoso, P ;
Pereira, T ;
Soares, J .
ACTA ONCOLOGICA, 2001, 40 (04) :472-478
[8]
Male and female breast cancer -: Differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis [J].
Andre, Saudade ;
Pinto, Antonio E. ;
Laranjeira, Catia ;
Quaresma, Manuela ;
Soares, Jorge .
PATHOBIOLOGY, 2007, 74 (06) :323-327
[9]
ANELLI TFM, 1994, CANCER, V74, P74
[10]
Aromatase inhibitors and male breast cancer [J].
Arriola, E. ;
Hui, E. ;
Dowsett, M. ;
Smith, I. E. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (03) :192-194